2055362-72-4
Benzoic acid, 4-[5-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-
CAS: 2055362-72-4
Molecular Formula: C22H15NO4S2
2055362-72-4 - Names and Identifiers
2055362-72-4 - Physico-chemical Properties
| Molecular Formula | C22H15NO4S2 |
| Molar Mass | 421.49 |
| Density | 1.50±0.1 g/cm3(Predicted) |
| Boling Point | 634.7±65.0 °C(Predicted) |
| pKa | 4.11±0.10(Predicted) |
| In vitro study | (Z)-Leukadherin-1 (ADH-503 free base; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b + cells and subsets of CD11b + monocytes, granulocytes, eosinophils, and macrophages. |
2055362-72-4 - References
| biological activity | (Z)-Leukadherin-1 (ADH-503 free base) is an orally active, allosteric CD11b agonists. (Z)-Leukadherin-1 can lead to tumor-associated macrophage repolarization, reduce the number of tumor-infiltrating immunosuppressive bone marrow cells, and enhance dendritic cell responses. |
| Target | CD11b |
| Animal Model: | KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras G12D /p53 flox/flox ] Male rats |
| Dosage: | 30, 60, or 120 mg/kg 30, 100 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral gavage; 60 days Oral gavage twice a day; on days 1 and 5 |
| Result: | Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival. Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively. |
Last Update：2024-04-09 02:00:19
